Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027

Zura Bio Ltd

Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
Net loss improved to $45.4M ($0.60 per share) from $69.2M ($2.09 per share) in 2023.
Initiated Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis (SSc) in Dec 2024; Phase 2 HS trial planned for Q2 2025.
Completed $112.5M private placement in April 2024; also executed warrant exchange and established ATM program in 2024.
Robert Lisicki appointed CEO in April 2024; Kiran Nistala joined as CMO in Jan 2024; Scientific Advisory Board established June 2024.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-027504
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2025-03-25T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.336470+00:00
generated_at: 2026-05-24T06:04:54.958590+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-027504
json_url: https://secwatch.observer/filing/0001104659-25-027504.json
markdown_url: https://secwatch.observer/filing/0001104659-25-027504.md
text_url: https://secwatch.observer/filing/0001104659-25-027504.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/0001104659-25-027504-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/tm2510115d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-027504

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.